Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:18:28 EDT Tue 17 Sep 2024
Enter Symbol
or Name
USA
CA



Q:REGN - REGENERON PHARMACEUTICALS INC - http://www.regeneron.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
REGN - Q1.01,148.88·1,156.001.21,153.08-0.270.0346.9399,86210,6651,162.05  1,162.05  1,152.011,211.1999  769.1918:08:35Sep 1315 min RT 2¢

Recent Trades - Last 10 of 10665
Time ETExPriceChangeVolume
18:08:35Q1,156.002.651
17:57:02Q1,151.93-1.421
17:23:16Q1,150.40-2.954
17:10:25Q1,150.50-2.852
17:04:09Q1,153.08-0.271,229
16:32:03Q1,157.604.251
16:20:00Q1,153.08-0.271,287
16:15:04Q1,153.08-0.271
16:07:14Q1,153.08-0.271
16:02:17Q1,153.08-0.2717

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-09-13 12:15U:REGNNews ReleaseDupixent(TM) (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
2024-09-11 07:01U:REGNNews ReleaseEYLEA HD(TM) (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
2024-09-11 01:04U:REGNNews ReleaseDupixent(TM) (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
2024-09-11 00:59U:REGNNews ReleaseDupixent(TM) (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
2024-09-09 17:00U:REGNNews ReleaseLibtayo(TM) (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
2024-09-09 07:00U:REGNNews ReleaseRegeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
2024-08-26 07:00U:REGNNews ReleaseOrdspono(TM) (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
2024-08-26 01:00U:REGNNews ReleaseLatest Dupixent(TM) (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
2024-08-20 18:45U:REGNNews ReleaseRegeneron Provides Update on Biologics License Application for Linvoseltamab
2024-08-07 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentations and Oncology Investor Webcast
2024-08-01 06:30U:REGNNews ReleaseRegeneron Reports Second Quarter 2024 Financial and Operating Results
2024-07-31 07:30U:REGNNews ReleaseRegeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
2024-07-03 01:00U:REGNNews ReleaseDupixent(TM) (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
2024-06-28 07:00U:REGNNews ReleaseOdronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
2024-06-27 16:05U:REGNNews ReleaseRegeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
2024-06-26 17:30U:REGNNews ReleaseDupixent(TM) (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
2024-06-16 06:10U:REGNNews ReleaseUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
2024-06-11 07:00U:REGNNews ReleaseKevzara(TM) (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
2024-05-31 01:05U:REGNNews ReleaseDupixent(TM) (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
2024-05-31 01:00U:REGNNews ReleaseUpdate on FDA Priority Review of Dupixent(TM) (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation